Close
Almac
Achema middle east

Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -
  • 02 NHS Workers have reportedly suffered from allergic reactions from the first jab of Pfizer-BioNtech COVID-19 vaccine in the UK.
  • MHRA has issued an advisory asking people with an allergic history to refrain from vaccination.

An air of apprehension is doing rounds as this week sees the UK administering the much-awaited Pfizer COVID vaccine shots to its citizens. Two days on and the first warning signal has been issued by British Healthcare regulator asking people with a history of allergies not to take the vaccine. This advisory came to the fore as two NHS healthcare workers suffered allergic reactions to the first jab.

Since this has taken place, an advisory has been floated by MHRA to people who are easily susceptible to medicines, food, and vaccines. These allergic reactions were however not seen across the sample size during the extensive clinical trials that were conducted. The two healthcare workers developed an anaphylactoid reaction shortly after they were administered the COVID-19 vaccine. Although they are stable now, yet a few eyebrows are already raised doubting the prolonged effects of the vaccine. The reactions caused due to anaphylactoid mostly appear as skin rashes, breathlessness and a dip in the blood pressure.

Pfizer has confirmed that they have been advised by the MHRA about the two yellow card reports and are giving the agency all the required support in the investigation.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »